Screener / SEC EDGAR /CIK 0001368514 /10-K filed Feb 25, 2026, compared with Mar 18, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Biotechnology

Adma Biologics, Inc. ADMA

Compare with peers Embed
Why it changed

The biggest changes in the 10-K filed Feb 25, 2026, in management's words

10-K, Item 7

This fiscal year against the last, and the sentences in the MD&A where management explains each change. Tickdelta picks sentences that name the line, a direction and a cause. It does not write explanations of its own.

Gross margin

Big change, FY to Dec 31, 2025 vs Dec 31, 2024

51.5% to 57.4% (+5.9 pts)

“The improvement in gross margin is mainly driven by a significantly more favorable mix of higher margin IG sales in 2025 as compared to 2024, along with the reduction in other manufacturing costs.”

Read it in the 10-K

Cash from operations

Big change, FY to Dec 31, 2025 vs Dec 31, 2024

-57.5%

The MD&A has no sentence that names a cause for this change.

Operating margin

Big change, FY to Dec 31, 2025 vs Dec 31, 2024

32.6% to 37.5% (+4.9 pts)

“Plasma center operating expenses, which primarily consist of compensation, benefits and travel for plasma center management and administrative staff increased to $4.8 million for the year ended December 31, 2025 as compared to approximately $4.2 million for the year ended December 31, 2024.”

Read it in the 10-K

Net income

Big change, FY to Dec 31, 2025 vs Dec 31, 2024

-25.7%

“Other income, net, for the year ended December 31, 2025 was $1.7 million, as compared to $1.9 million for the year ended December 31, 2024, driven by the decrease in 2025 of the prevailing short-term interest rates which resulted in lower interest income.”

Read it in the 10-K

Revenue

Big change, FY to Dec 31, 2025 vs Dec 31, 2024

+19.6%

“The increase in total revenue is primarily related to increased sales of ASCENIV, as we continue to experience increased physician, payer and patient acceptance and utilization of this product, partially offset by the decrease in sales of BIVIGAM, intermediates and other.”

Read it in the 10-K

What management said, year by year

The cause given in each 10-K, 2 fiscal years, newest first · MD&A (Item 7)

Each bar is how the line changed that year (from the same 10-K's XBRL). Under it, the sentence in that year's MD&A that names the line, a direction and a cause, word for word. A year with no sentence says so.

Revenue

2 of 2 years explained
  • FY 2025 +19.6%

    “The increase in total revenue is primarily related to increased sales of ASCENIV, as we continue to experience increased physician, payer and patient acceptance and utilization of this product, partially offset by the decrease in sales of BIVIGAM, intermediates and other.”

    Read it in the FY 2025 10-K
  • FY 2024 +65.2%

    “product revenue costs related to our increased sales of IG products and plasma of $39.5 million and $3.1 million, respectively, partially offset by a reduction in other manufacturing costs, mainly unabsorbed manufacturing expenses, of $5.1 million.”

    Read it in the FY 2024 10-K

Gross margin

2 of 2 years explained
  • FY 2025 +5.9 pts

    “The improvement in gross margin is mainly driven by a significantly more favorable mix of higher margin IG sales in 2025 as compared to 2024, along with the reduction in other manufacturing costs.”

    Read it in the FY 2025 10-K
  • FY 2024 +17.0 pts

    “The improvement in gross margin is mainly driven by a significantly more favorable mix of higher margin IG sales in 2024 as compared to 2023, along with the reduction in other manufacturing costs.”

    Read it in the FY 2024 10-K

    “improved gross profit, driven by both the year-over-year revenue growth and the shift in revenue mix toward significantly higher margin IVIG products, partially offset by $13.3 million of higher total operating expenses.”

    Read it in the FY 2024 10-K

Operating margin

2 of 2 years explained
  • FY 2025 +4.9 pts

    “Plasma center operating expenses, which primarily consist of compensation, benefits and travel for plasma center management and administrative staff increased to $4.8 million for the year ended December 31, 2025 as compared to approximately $4.2 million for the year ended December 31, 2024.”

    Read it in the FY 2025 10-K
  • FY 2024 +24.2 pts

    “Selling, general and administrative (“SG&A”) expenses were $74.1 million for the year ended December 31, 2024, an increase of $15.1 million from the year ended December 31, 2023, and reflects an increase in”

    Read it in the FY 2024 10-K

    “operating income/loss of $61.0 million and the $1.9 million increase in other income/expense, partially offset by a higher loss on extinguishment of debt of $19.5 million and higher interest expense of $5.7 million.”

    Read it in the FY 2024 10-K

Cash from operations

0 of 2 years explained
  • FY 2025 -57.5%

    The FY 2025 MD&A has no sentence that names a cause for this change.

  • FY 2024 +1248.5%

    The FY 2024 MD&A has no sentence that names a cause for this change.

Changes are computed from the XBRL figures in the same 10-K. Hover a number to see the line item. Open the 10-K

Sources

The Management's Discussion and Analysis (Item 7) of the latest 10-K, quoted word for word; the changes are computed from the same 10-K's XBRL.

Also

Financials: the numbers year by year.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ADMA/export.csv") into a cell.

Next:Accounting checks
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.